Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash	$ 78,081	$ 474,019
Restricted cash	20,000	20,000
Accounts receivable	69,806	19,748
Prepaid & other current assets	20,946	101,869
Total current assets	188,833	615,636
Development equipment, net of depreciation of $109,419 and $101,810	2,539	10,148
Intangibles, net of accumulated amortization of $175,497 and $136,974	834,683	873,206
In process R&D	1,101,760	1,101,760
Goodwill	21,062,455	21,062,455
Total assets	23,190,270	23,663,205
Current liabilities:
Accounts payable and accrued liabilities	4,406,807	2,735,805
Accounts payable to related party	425,740	391,631
Contingent Consideration	2,625,000	2,625,000
Derivative liability on Notes	393,161	777,024
Convertible debt for clinical trial	2,050,409	2,000,000
Convertible debt, net of costs	1,941,490	1,091,612
Convertible debt, related party, net of costs	690,518	297,989
Private Placement convertible note, net of costs	2,073,480	943,586
Private Placement convertible note, related party, net of costs	101,115	67,992
Payroll Protection Plan loan	92,995	251,733
Total current liabilities	14,800,715	11,182,372
Commitments and contingencies (Note 12)
Stockholders’ equity:
Convertible Preferred stock, $0.01 par value, 15,000,000 shares authorized; 0 and 278,188 shares issued and outstanding		2,782
Common stock, $.01 par value; 750,000,000 and 150,000,000 shares authorized; 372,564,911 and 90,601,912 issued and outstanding, respectively	3,725,649	906,019
Additional paid-in capital	33,511,091	32,493,086
Accumulated deficit	(29,226,896)	(21,630,008)
Total Oncotelic Therapeutics, Inc. stockholders’ equity	8,009,844	11,771,879
Non-controlling interests	379,711	708,954
Total stockholders’ equity	8,389,555	12,480,833
Total liabilities and stockholders’ equity	$ 23,190,270	$ 23,663,205